After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...

Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

Asthma is a serious chronic condition, and it’s best managed with the help of a ... remedy for asthma in addition to these first-line treatments, and there is some evidence that it may help ...

Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers to dry powder inhalers and vice versa.

According to Research by SNS Insider, Nebulizer Market Growth is Driven by Rising Prevalence of Chronic Respiratory Diseases and Technological Advancements.Austin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

They also obtained smoking cessation treatment, exercise and weight counseling, and pneumonia and flu vaccines, if appropriate. Of the people seen by a lung specialist or asthma/COPD educator ...

Background: For several years, asthma and COPD have been regarded as distinct entities, with distinct clinical courses. However, despite distinctive physiologic features at the time of diagnosis ...

Steroid tablets are associated with significant adverse side effects. Short-term use risks sleep disturbance, reflux, ...

Full session details can be accessed on the ACAAI website. The poster will be available on the publications page of the Apogee website on October 24.

N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.